The Cognitive Neuroscience Program seeks highly innovative and interdisciplinary proposals aimed at advancing a rigorous understanding of how the human brain supports thought, perception, affect, action, social processes, and other aspects of cognition and behavior, including how such processes develop and change in the brain and through time.
The goal of this Funding Opportunity Announcement (FOA) is to support preliminary steps in the preclinical development of therapeutics for neurological disorders. Such projects, if successful, should lead directly to a subsequent project that will include all remaining activities for submission of an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application to the Food and Drug Administration (FDA). The scope includes only therapy development activities, so development of diagnostics, biomarkers, or rehabilitation strategies cannot be supported. Clinical research, basic research, and studies of disease mechanism are outside program scope.
This Funding Opportunity Announcement (FOA) encourages research grant applications from applicant organizations directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function.
This Funding Opportunity Announcement (FOA) encourages research grant applications from applicant organizations directed toward the discovery of the impact of alterations associated with complex brain disorders on the fundamental cellular and molecular substrates of neuronal function.
This funding opportunity announcement (FOA) encourages research grant applications from institutions/organizations to develop novel, robust analytical platforms using in vitro assays to reveal changes in neuronal and/or glial function.The goal is to adapt state-of-the-art measures of basic cellular processes or molecular events that are key mediators of nervous system function with the intent to probe mechanisms and/or perturbations in an unbiased and efficient manner.The novel assay platforms would provide opportunities to measure neurobiological endpoints and build a pipeline to be used in the context of target identification and drug discovery.
This FOA issued by the National Institute on Aging (NIA), National Institutes of Health, encourages grant applications from institutions/organizations that propose to develop research on single cell biology to enhance the understanding of the mechanisms of normal aging and of age-related diseases.Applications using -omics technologies, imaging, optofluidic platforms, mass spectroscopy, whole genome sequencing, and other tools and technologies at the single cell level are encouraged since it is expected that the single cell approach will improve the determination of unique and biologically significant properties of tissues and organs during the aging process.
Although we know that cells are heterogeneous, for example they might be at different stages in the cell cycle or at different stages in tumor progression, most contemporary studies use population of cells, thus providing a limited average view of cellular and tissue function.This is due mainly to the lack of tools to study single cells.This is now changing.Advances in technology have made more single cell studies feasible and will convert cellular heterogeneity from a source of noise to a source of new discoveries.
This FOA issued by the National Institute on Aging (NIA), National Institutes of Health, encourages grant applications from institutions/organizations that propose to develop research on single cell biology to enhance the understanding of the mechanisms of normal aging and of age-related diseases.Applications using -omics technologies, imaging, optofluidic platforms, mass spectroscopy, whole genome sequencing, and other tools and technologies at the single cell level are encouraged since it is expected that the single cell approach will improve the determination of unique and biologically significant properties of tissues and organs during the aging process. Although we know that cells are heterogeneous, for example they might be at different stages in the cell cycle or at different stages in tumor progression, most contemporary studies use population of cells, thus providing a limited average view of cellular and tissue function.This is due mainly to the lack of tools to study single cells.This is now changing.Advances in technology have made more single cell studies feasible and will convert cellular heterogeneity from a source of noise to a source of new discoveries.
Agency:NIH-National Institutes of Health
Number:PAR-12-053
Deadline:Letter of Intent: One month prior to application due date
Full Application: February 5, 2012; June 5, 2012; October 5, 2012
The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications to pursue translational and pilot clinical studies for neural prosthetics. The program will utilize the cooperative agreement mechanism to enable support for milestone-driven projects for the development and demonstration of clinically-useful neural prosthetic devices. Activities supported in this program include implementation of clinical prototype devices, preclinical safety and efficacy testing, design verification and validation activities, pursuit of regulatory approval for clinical study, and proof-of-concept or pilot clinical studies.
